What Acupath’s ArteraAI Prostate Test rollout reveals about the next phase of precision oncology
Acupath adds ArteraAI Prostate Test to its pathology workflow. Find out what it means for AI prostate cancer risk stratification today.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
What Roche’s $1.05bn PathAI move reveals about the future of pathology labs
Roche wants AI pathology at scale. PathAI gives it the tissue-analysis layer needed to tighten diagnostics, trials, and precision oncology.
Medical Devices & Diagnostics
TytoCare just opened a new FDA category. Can AI make home ear exams clinically useful?
Home diagnostics need regulatory trust. TytoCare’s FDA De Novo win tests whether AI can move ear exams beyond video visits.
Medical Devices & Diagnostics
BostonGene AI framework identifies actionable targets in 65% of cancer of unknown primary cases at USCAP 2026
BostonGene presents multimodal AI CUP framework at USCAP 2026, identifying actionable targets in 65%+ of patients. Read the analysis.
Medical Devices & Diagnostics
Ozelle’s 100B-image diagnostic AI platform puts scale and precision at the center of care
Ozelle’s AI-powered CBM platform debuts at WHX Dubai 2026. Discover how modular, guided diagnostics are transforming primary and veterinary care workflows.
Medical Devices & Diagnostics
Can PathoCare’s $1.75bn tender offer reprice the future of AI-driven diagnostics?
Find out why PathoCare's $1.75B valuation and expanded $50M financing round could signal a breakthrough moment for AI-powered point-of-care diagnostics.
Features & Analysis
Is AI finally ready to close the equity gap in breast cancer screening in the United States and beyond?
The rapid progress of artificial intelligence in medical imaging is creating fresh optimism among healthcare leaders seeking to close the persistent equity gap in breast cancer screening. The regulatory push by Lunit, a Seoul-based AI diagnostics firm, for its Lunit INSIGHT Risk model, which estimates a woman’s five-year breast cancer risk directly from mammogram images,
Medical Devices & Diagnostics
Can Geneva PE’s NXXIM platform fix fragmentation in diagnostic imaging?
Geneva Private Equity has launched NXXIM, a new AI-powered enterprise medical imaging platform designed to unify radiology, pathology, genomics, and electronic health record data into a single, real-time diagnostic environment. The investment-backed venture will pilot its platform in clinical settings in 2026, aiming to streamline fragmented workflows and reduce time-to-diagnosis for large health systems. What